Patients with stroke who receive intra-arterial thrombolysis after thrombectomy are more likely to achieve superior 90-day ...

Please provide your email address to receive an email when new articles are posted on . NEW YORK — Vitrectomy using balanced saline solution without tissue plasminogen activator is effective for ...

SEATTLE--(BUSINESS WIRE)--According to Coherent Market Insights, the global tissue plasminogen activator market is estimated to be valued at US$ 2,455.4 million in 2020 and is expected to exhibit a ...

The clot-busting drug tissue plasminogen activator (tPA) is currently the only FDA-approved therapy for acute stroke. However, increasing evidence suggests that tPA can also contribute to excitotoxic ...

Recombinant tissue plasminogen activator (tPA) is a Food and Drug Administration-approved thrombolytic treatment for ischemic stroke. tPA is also naturally expressed in glial and neuronal cells of the ...

Thrombolex, Inc. announced findings from a prespecified interim analysis from the first 50 patients in the postmarket RAPID-PE ...

Patients. Twenty-six preterm infants, who were consecutively admitted to the neonatal intensive care unit of the Beatrix Childrens Hospital, University Hospital, Groningen, were studied. These infants ...

If approved, the targeted IGF-1 fusion protein would become the only treatment available for late-window stroke patients ...

Panel A shows second-degree frostbite of the foot after rewarming, with clear blisters and pink toes. Perfusion was detected in the toes. Thrombolysis was not advised, and the patient did well with ...